title: [Evaluation of first phase insulin secretion by a nateglinide-intravenous glucose insulin release test in newly diagnosed type 2 diabetics].
abstract: OBJECTIVE
  To evaluate the function of the first phase of insulin secretion of pancreatic B cells in newly diagnosed type 2 diabetics using nateglinide-intravenous glucose insulin release test (NG-IVGIRT).
  
  
  METHODS
  NG-IVGIRT and intravenous glucose insulin release test (IVGIRT) were done in 8 patients with newly diagnosed type 2 diabetes mellitus and NG-IVGIRT was done in 8 normal people. Insulin and glucose of blood were determined at - 15, 0, 2, 4, 6, 8 and 10 min in NG-IVGIRT or IVGIRT.
  
  
  RESULTS
  The response of 0 - 10 min insulin to NG-IVGIRT was significantly higher than that to IVGIRT in the diabetics. The response of insulin to NG-IVGIRT in the normal controls was much higher than that in the diabetics. The area under curve (AUC) of insulin to NG-IVGIRT was apparently elevated and the AUC of glucose to NG-IVGIRT reduced in the normal controls as compared with those in the diabetics.
  
  
  CONCLUSIONS
  The results indicated that the reserve of first phase insulin secretion in newly diagnosed type 2 diabetics could be provoked in some degree by NG-IVGIRT and there was a big difference in the reserve of the first phase of insulin secretion provoked by NG-IVGIRT between newly diagnosed type 2 diabetics and normal people.
authors.affiliation: Department of Endocrinology, Affiliated Shenzhen Hospital, Nafang Medical University, Shenzhen 518035, China. lgchun@163.com
authors.forename: Guo-chun
authors.initials: GC
authors.lastname: Luo
authors.forename: Zhen
authors.initials: Z
authors.lastname: Liang
authors.forename: Qing-hong
authors.initials: QH
authors.lastname: Hu
authors.forename: Jie
authors.initials: J
authors.lastname: Chai
authors.forename: Ming-zheng
authors.initials: MZ
authors.lastname: Li
authors.forename: De-wen
authors.initials: DW
authors.lastname: Yan
authors.forename: Hai-yan
authors.initials: HY
authors.lastname: Li
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D003510:Cyclohexanes / Q000494:pharmacology; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology*; D005069:Evaluation Studies as Topic; D005260:Female; D005947:Glucose / Q000494:pharmacology; D005951:Glucose Tolerance Test / Q000592:standards; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D007328:Insulin; D000077715:Nateglinide; D010649:Phenylalanine; D005947:Glucose